The main objective of EBOVAC2 is to provide extensive and robust data on the safety and immunogenicity of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.

This will be done by:

1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates; 

2. Carrying out Phase 2 trials in African and European volunteers Given the compressed nature of this development program, the Phase 2 studies are anticipated to be conducted in parallel with the planned Phase 3 study (EBOVAC1). The Phase 2 studies will be controlled with either placebo or active control vaccinations with standard vaccines and will be conducted in locations where it is possible to perform carefully controlled safety studies;

3. Evaluating the use of the vaccine regimen in healthy population groups, such as children (aged 1-17 years), the elderly (ages 50-65) and individuals infected with HIV, to confirm safety and immunogenicity. It is intended that Phase 2 trials will begin as soon as preliminary safety data are available from Phase 1 trials;

4. Monitoring and characterising immune response to the proposed vaccine regimen;

5. Boosting the capacity of African centres and staff as well as communicating and disseminating the results of EBOVAC2 as they become available to all key stakeholders;

6. Contributing all data to the Central Information Repository (set up in EBOVAC1) for use by all Ebola+ programme projects as well as the wider community.

laboratory compressed                                                    © Janssen


  • 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here :

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research